Zai Lab Ltd - Company Profile
Powered by 
All the data and insights you need on Zai Lab Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Zai Lab Ltd Strategy Report
- Understand Zai Lab Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Zai Lab Ltd (Zai Lab) is a commercial-stage biopharmaceutical company. It discovers, develops and commercializes innovative products in the areas of oncology, autoimmune disorders, infectious disease and neuroscience. The company offers products such as niraparib, tumor-treating fields, efgartigimod, ripretinib and omadacycline. It’s pipeline products include tisotumab vedotin, adagrasib, repotrectinib, bemarituzumab, zipalertinib, ZL-1218, ZL-1310, sulbactam-durlobactam, KarXT, ZL-1102, ZL-8301, Efgartigimod PH20 SC, ZL-2308 (repotrectinib), ZL-1307 (REGN1979/odronextamab) and ZL-1218. Zai Lab commercializes its products under the brand names Optune, Qinlock, Zejula, NUZYRA and VYVGART. The company operates through its subsidiaries in Hong Kong, Taiwan, China, Australia and the US, among others. Zai Lab is headquartered in Shanghai, China.
Headquarters
China
Address
Building 1, 4th Floor Jinchuang Plaza, 4560 Jinke Road, Shanghai, 201210
Website
www.zailaboratory.com
Telephone
86 21 61632588
No of Employees
2,175
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZLAB (NASD)
Revenue (2022)
$266.7M
24%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
24.5%
(2022 vs 2021)
Market Cap*
$1.6B
Net Profit Margin (2022)
XYZ
39.1%
(2022 vs 2021)
* As of and is in US$
Zai Lab Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Niraparib: Ovarian Cancer | Optune |
| Tumor Treating Fields: | Qinlock |
| Glioblastoma | Zejula |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In April, the company announced a strategic partnership and exclusive worldwide license agreement with MediLink Therapeutics to expand lung cancer franchise and global oncology pipeline with YL212. |
| 2022 | New Products/Services | In October, the company announced the launch of its 2022 trust report. |
| 2022 | Contracts/Agreements | In September, Seagen Inc and Zai Lab Limited announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan. |
Competitor Comparison
| Key Parameters | Zai Lab Ltd | Livzon Pharmaceutical Group Co Ltd | Innovent Biologics Inc | Hainan Haiyao Co Ltd | Bio-Thera Solutions Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Zhuhai | Suzhou | Haikou | Guangzhou |
| State/Province | Shanghai | Guangdong | Jiangsu | Hainan | Guangdong |
| No. of Employees | 2,175 | 8,933 | 4,872 | 2,247 | 1,167 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Samantha Du, Ph.D. | Chairman; Chief Executive Officer | Executive Board | 2014 | 59 |
| Ning Xu, M.D. | Head - Clinical Operations; Executive Vice President | Executive Board | - | - |
| Yajing Chen, Ph.D. | Chief Financial Officer | Senior Management | 2023 | 56 |
| Joshua Smiley | Chief Operating Officer; President | Senior Management | 2022 | 50 |
| F. Ty Edmondson | Chief Legal Officer | Senior Management | 2020 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer